Protein tyrosine kinases play critical roles in cell signaling and are considered attractive targets for drug discovery. The authors have applied µARCS (microarrayed compound screening) technology to develop a high-throughput screen for finding inhibitors of the p56 lck tyrosine kinase. Initial assay development was performed in a homogeneous time-resolved (LANCE™) format in 96-well microplates and then converted into the gel-based µARCS format. The µARCS methodology is a well-less screening format in which 8640 compounds are arrayed on a microplate-sized piece of polystyrene and subsequently assayed by placing reagents cast in agarose gels in contact with these compound sheets. A blotting paper soaked with adenosine triphosphate is applied on the gel to initiate the kinase reaction in the gel. Using this screening methodology, 300,000 compounds were screened in less than 40 h. Substantial reagent reduction was achieved by converting this tyrosine kinase assay from a 96-well plate assay to µARCS, resulting in significant cost savings. (Journal of Biomolecular Screening 2004:12-21) Key words: protein tyrosine kinases, drug discovery, microarrayed compound screening (µARCS), high-throughput screening 12 www.sbsonline.org
INTRODUCTION
P ROTEIN TYROSINE KINASES (PTKs) play a significant role in signal transduction pathways that are crucial for a number of cellular functions, including proliferation, differentiation, adhesion, motility, and cell death. 1 These enzymes are attractive cell-signaling targets for the identification and development of therapeutic agents for diseases involved with the overexpression or abnormal activation of PTKs. 2, 3 Many selective tyrosine kinase inhibitors are currently in different stages of clinical trials for several diseases, including various cancers, while Gleevec™ (imatinib mesylate), a BCR-ABL tyrosine kinase inhibitor, has already been approved by the Food and Drug Administration (FDA) for the treatment of chronic myeloid leukemia. 4 p56 lck (lck), a member of the Src family of tyrosine kinases, is present in T cells and plays a vital role in the activation response from the T cell receptor (TCR) intracellular domain to other signaling proteins. 5 Antigen-induced T cell activation is characterized by the appearance of a p56 lckdriven hyperphosphorylated TCR ζ-chain, a critical event necessary for recruitment of the syk family kinase ZAP-70 to the TCR signaling complex. This results in interleukin 2 gene expression and triggering of effector functions. 6 T cells that lack functional lck are not capable of responding to stimulation through the T cell receptor, 7 and hence an inhibitor of lck should effectively block T cell function, act as an immunosuppressive agent, and have potential therapeutic utility in treating autoimmune diseases and solid organ transplant rejection.
Microarrayed compound screening (µARCS), a gel-based, well-less, ultra-high-throughput screening platform, has been used successfully to screen a variety of target classes at Abbott Laboratories. 8, 9 We have used this screening format for homogeneous assays in addition to more complex nonhomogeneous assays. [10] [11] [12] Most of the assay components for this assay are incorporated into 1% agarose gels, although other reagents can be more conveniently introduced into the assay using membranes and filter papers as reagent carriers. The beauty of µARCS lies in the fact that while providing incredible throughput with very little automation, this format significantly reduces the amounts of reagents required for screening, thus reducing the cost of the assay. Time-resolved fluorescence resonance energy transfer (TR-FRET) assays for tyrosine kinases are shown to be sensitive and efficient for high-throughput screening (HTS) in the microplate. 13 A 96-well TR-FRET assay was developed and then readily converted into a µARCS screen to find the inhibitors of p56 lck tyrosine kinase. We used the LANCE™ technology, the TR-FRET platform from PerkinElmer, for the detection of phosphorylated and biotinylated p56 lck substrate using energy transfer from a Eu-labeled phosphotyrosine antibody to the streptavidin-conjugated APC (Surelight® allophycocyanin). In this article, we present in detail the methodologies used to develop a 96-well plate and µARCS assay to identify novel and potent inhibitors of p56 lck .
MATERIALS AND METHODS

Materials/reagents
Costar 96-well black flat-bottom polystyrene plates (Corning, Inc., Corning, NY) were used for the assay. p56 lck enzyme (MVL-LCK N64-509) was expressed and purified at Abbott Laboratories. Biotinylated substrate (Biotin-Ahx-GAEEEIYAAFFA-COOH) was synthesized by SynPep Corp. (Dublin, CA). The LANCE™ detection reagents, streptavidin-conjugated allophycocyanin (APC-streptavidin), and Eu-labeled phosphotyrosine antibody (Eu-anti-p-Tyr Ab) were purchased from PerkinElmer Life Sciences/Wallac Research (Turku, Finland). The high-gel strength, low-melt temperature agarose was purchased from BioWhittaker Molecular Applications (Rockland, ME). Reagents were applied to the gel using Pall A/E glass fiber filter paper (Gelman Sciences, Ann Arbor, MI).
96-Well microplate format
Kinase assay. The kinase reaction was performed in a final reaction volume of 40 µL. Compounds and control inhibitors were added to the plates in DMSO, with a final DMSO concentration of 5% in each reaction well. Enzyme and substrate were diluted in the assay buffer (50 mM MOPS [pH 7.5], 10 mM MgCl 2 , 2 mM MnCl 2 , 2.5 mM dithiothreitol [DTT], 0.01% bovine serum albumin [BSA], 0.1 mM activated sodium orthovanadate are final assay concentrations) and added together in a volume of 28 µL to provide final concentrations of 4 ng/well and 2 µM, respectively. The reaction was initiated by the addition of 10 µL of adenosine triphosphate (ATP) (diluted in water) to a final concentration of 50 µM. The plates were incubated for 50 min at ambient temperature, and then the reaction was stopped by the addition of 1.6 µL ethylenediaminetetraacetic acid (EDTA) (pH 8.0) to a final concentration of 20 mM to chelate the Mn 2+ . For detection, the LANCE™ reagents, APC-streptavidin, and Eu-anti-p-Tyr Ab were diluted in detection buffer (25 mM Tris-HCl [pH 7.5], 150 mM NaCl, 0.1% BSA) and added together at a concentration of 2.5 µg/mL and 1 nM, respectively, in a volume of 150 µL. The plates were read immediately in a Victor 2 V multilabel plate reader (PerkinElmer Life Sciences) using the LANCE™ 615/665 counting protocol. The Victor 2 V settings included a 111 flash energy with a 50-µsec delay and a signal acquisition time of 100 µsec. The APC-streptavidin binds the biotin moiety of the substrate, while the Eu-anti-p-Tyr Ab binds the phosphorylated tyrosine of the substrate. When bound in close proximity, the europium, which is excited at 340 nm, transfers the energy to the APC, which in turn emits at 665 nm. The presence or absence of the 665nm signal indicates the phosphorylation state of the substrate and thus the inhibitory capabilities of any compound added to the assay.
ARCS format
Compound preparation. Compounds to be screened were arrayed onto polystyrene sheets (Tekra Corp., New Berlin, WI) that have the same footprint as a microplate using a PixSys nQuad™ dispenser (Cartesian Technologies, Irvine, CA). Compounds were spotted at a 1-mm distance using a 40-nL volume of 5-mM stock solutions to give approximately 200 pmol of compound per spot. Then, 8640 compounds were spotted on these sheets in 2 different patterns, the normal and deconvolution sheets. In the primary screen, both sheets were assayed, so all compounds were assessed for activity in duplicate. This deconvolution format facilitates identification of a single active compound because each compound is tested on 2 different sheets in spatially distinct locations and within a unique group of neighboring 25 compounds that comprise the center compound, the 8 surrounding that (shell 1), and the 16 compounds outside shell 1 (shell 2). The compound sheets were dried under vacuum and stored sealed in Mylar bags at -80°C until use. Constellation spots (dye markers) were also spotted on the sheet, which assist in orienting the sheet in the image analysis program and identifying active compounds for retesting. For retesting, compounds were arrayed at a 384 density on polystyrene sheets and tested in duplicate. For both primary and retest sheets, a dilution of a control compound was spotted outside the compound array area and allowed to dry. This was used to evaluate the performance of the assay. IC 50 determinations of active compounds were performed in the 96-well plates as described previously.
Gel preparation. The enzyme, substrate, and detection reagents were all embedded into a 0.75-mm thick low-melting point 1.1% agarose gel cast in a gel-casting apparatus (Discovery Partners International, San Diego). The agarose gel solution was prepared by boiling all nonheat-labile components of the assay buffer (MOPS, MgCl 2 , MnCl 2 ) with the agarose until melted, then holding the gel at 37°C in a water bath. The remaining components of the assay buffer were added to the 37°C gel solution (DTT, BSA, sodium orthovanadate, and DMSO at 5%), as well as the enzyme at 2 ng/ µL, substrate at 2 µM, APC-streptavidin at 2.5 µg/mL, and Euanti-p-Tyr Ab at 2 nM. After addition of the heat-labile components, the gel was cast immediately and cooled to 16°C for 10 min.
Gel assay. The gel was air-dried for 10 min to remove excess moisture, then placed onto the polystyrene sheet containing the test compounds for 10 min to allow the diffusion of compounds into the gel containing assay components. The gel was removed from the compound sheet, and 50 µM ATP (diluted in assay buffer with 5% DMSO added) was applied to the gel with a sheet of glass fiber filter paper wetted with the ATP solution for 10 min. This sheet was removed after 25 min and replaced by a second glass fiber filter paper wetted with 0.5 M EDTA, pH 8.0, applied for 5 min to stop the kinase reaction and to chelate the metals that interfere with the efficiency of detection reagents. The gel was then imaged (λ ex = 340 nm and λ em = 665 nm) in a ViewLux CCD imaging system (PerkinElmer Life Sciences) at an excitation energy of 320,000 for 75 sec.
RESULTS AND DISCUSSION
96-Well microplate format
Optimization of the reagent concentrations was first done in the 96-well plate format. The peptide, substrate, and enzyme concentrations were optimized in an experiment in which substrate concentrations ranging from 0, 1, 2, and 4 µM were each titrated against the enzyme concentrations of 0, 1.25, 2.5, 5, 10, and 20 ng/ well while maintaining the ATP concentration constant at 50 µM. As shown in Figure 1A , the signal increased with increasing con- The enzyme titration and time study was conducted to determine the optimal concentration of the enzyme and incubation time. This enzyme was titrated at 2 (solid squares), 3 (solid triangles), 4 (solid circles), and 5 (solid diamonds) ng/well in the presence of 2 µM substrate and 50 µM ATP. The reaction was incubated from 0 to 70 min. The Eu-anti-p-Tyr Ab and APC-streptavidin concentration were maintained at 1 nM and 2.5 µg/mL, respectively. Results show mean ± SD (n = 2). (C) Optimization of ATP concentration. Dose-dependent inhibition of the enzyme by staurosporine was studied in the presence of ATP at 25 (solid triangles), 50 (solid circles), and 75 (solid squares) µM ATP. The enzyme concentration was maintained at 4 ng/well and substrate at 2 µM. The Eu-anti-p-Tyr Ab and APC-streptavidin concentration were maintained at 1 nM and 2.5 µg/mL, respectively. Results show mean ± SD (n = 2). (D) Optimization of Eu-anti-p-Tyr Ab concentration. Eu-anti-p-Tyr Ab was titrated at 0, 0.1, 0.5, 1, 2.5, and 5 nM. The enzyme concentration was maintained at 4 ng/well and substrate at 2 µM. The ATP was at 50 µM, and APC-streptavidin concentration was maintained at 2.5 µg/mL. Results show mean ± SD (n = 4). A time dependency study of the enzyme reaction was also performed for varying time intervals, with different concentrations of the enzyme ranging from 2, 3, 4, and 5 ng/well while maintaining the substrate at 2 µM and ATP at 50 µM (Fig. 1B) . To maintain the linear rate of reaction to increase the sensitivity of the assay, it was decided to conduct further optimizations of the assay with 4 ng/ well of the enzyme at an incubation time of 50 min. An ATP concentration experiment was performed in the presence of staurosporine, a kinase inhibitor (Fig. 1C) , to optimize the concentration of ATP in the kinase reaction. We determined an apparent Km for ATP for the p56 lck enzyme under the LANCE™ kinase assay condition as 15 µM (data not shown). The IC 50 s of staurosporine with 25, 50, and 75 µM ATP were 15, 33, and 45 nM, The Eu-anti-p-Tyr Ab was titrated to give an optimal signal in the LANCE™ reaction. As shown in Figure 1D , 1 nM Eu-anti-p-Tyr Ab provided a sufficient signal for a robust assay. Because the Eu-anti-p-Tyr Ab was by far the most expensive component in the assay, it was decided to keep this reagent at a concentration of 1 nM, even though the signal was higher using 5 nM. Divalent manganese cation is essential for the p56 lck kinase reaction; however, free Mn 2+ binds to the Eu-containing chelate and quenches the fluorescence of europium during the detection reaction. This quenching effect is prevented by addition of EDTA, which is used for chelating the free manganese. Unfortunately, it was also shown that free EDTA could compete for the Eu, thus reducing the excitation energy and diminishing the energy transfer to the APC acceptor. Therefore, it was very critical to maintain a well-defined concentration of EDTA in the assay, which was determined to be a final concentration of 20 mM. An experiment was performed to determine the optimal read time after addition of TR-FRET detection reagents, which showed no significant change in signal from time 0 to 3 h (data not shown); therefore, an immediate read was chosen. The sensitivity of DMSO in the assay was determined by adding varying amounts of DMSO in the reaction buffer from 0% to 7%. There was no inhibition by DMSO at any of the concentrations tested, and thus it was decided to use 5% DMSO in the reaction buffer to facilitate the solubilization of the test compounds. Finally, to assess the scatter in the assay, the Z′ factor 14 was calculated using a plate containing 48 wells of total controls and 48 wells of inhibited controls. The Z′ was determined to be 0.86, which shows the assay to have a very tight distribution.
ARCS Format
The 96-well plate assay was converted into the µARCS format to facilitate higher throughput screening of the Abbott drug repository. The assay components were optimized in the gel format where the plate-based reagent concentrations were used as an initial starting point. The enzyme was titrated at concentrations of 3, 2, 1, and 0.5 ng/µL while keeping the substrate at 2 µM and ATP at 50 µM. Eu-anti-p-Tyr Ab and streptavidin-APC were maintained at 2 nM and 2.5 µg/mL, respectively. Staurosporine was spotted onto polystyrene sheets to provide a range of 31 to 0.24 pmol concentration per spot. The sheets were dried in a vacuum oven prior to the reaction. The reaction was performed as described in the Materials and Methods. Inhibition zones appeared as dark areas on a fluorescent background ( Fig. 2A ). An enzyme concentration of 2 ng/µL was chosen for future experiments, as it provided a good signal with control inhibitor spots visible up to 0.48 pmol. While doing the preliminary experiments with enzyme in the gel, it was noted that the enzyme lost activity when the gel was warmed to greater than 37°C. Therefore, it was imperative to maintain the temperature of the agarose at 37°C for enzyme stability. In addition, the amount of time the enzyme was in warm agarose was limited to less than 1 min in all subsequent experiments. A titration of substrate was performed at 1, 2, and 3 µM, whereas enzyme concentration was maintained at 2 ng/µL, and ATP and other assay components were maintained the same as before (Fig. 2B) . A substrate concentration of 2 µM was chosen for the screening, which gave a good signal with the inhibitor spots visible up to 0.48 pmol. An experiment to optimize the ATP and Eu-anti-p-Tyr Ab concentrations was conducted (Fig. 2C) , and from the results, it was decided to maintain the ATP concentration at 50 µM and Eu-anti-p- 
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Tyr Ab at 2 nM. Optimization of the EDTA concentration to stop the reaction while chelating the Mn 2+ was performed (data not shown), and it was decided to use 20 mM EDTA for the future studies. Time dependence of the reaction in the µARCS format showed a steady increase in the signal, which reached a plateau response at 35 to 40 min (Fig. 2D ). An incubation period of 30 min was chosen for the µARCS format.
While doing the preliminary experiments, we incorporated the enzyme and substrate in a gel and started the reaction by adding ATP with a blotting paper. After stopping the reaction with EDTA, a gel containing the Eu-anti-p-Tyr Ab and APC-streptavidin was placed on top of the enzyme substrate gel, and the whole sandwich was imaged on a Viewlux immediately. After optimization of all the reagents and while screening a pilot set, we noticed that some biotin-containing compounds (circled) showed activity as inhibitors by competing with the biotinylated substrate for the APCstreptavidin (Fig. 3A) . To eliminate these nonspecific inhibitors, we reformatted the assay by incorporating the enzyme, substrate, Eu-anti-p-Tyr Ab, and APC-streptavidin in 1 gel and initiating the reaction by adding ATP soaked in blotting paper and stopping the reaction with EDTA-soaked paper. After removing the EDTAsoaked paper, we imaged the single gel, which contained all the reagents. As shown in Figure 3B . These values were plotted against the amount of staurosporine applied (in pmol), and the resulting IC 50 value was calculated to be 3.3 pmol (B). Results show mean ± SD (n = 2) from a representative experiment. This value compares favorably with the IC 50 value obtained from the plate format (33 nM, or 1.3 pmol) (C).
C duced by true inhibitors, which are present near the biotin compounds. Removal of these huge spots from the gel images simplified the picking of true hits by the screener. In addition, the staurosporine control inhibitor titers gave the same intensity of signal as the initial 2-gel method. This protocol also simplified the assay by eliminating the need for a second gel and thereby enhancing the throughput.
To determine the sensitivity of the µARCS format, the staurosporine inhibitory spots were quantified using the Scion Im-age software program (Scion Corp., Frederick, MD). The maximum pixel value for each spot was plotted against the amount of staurosporine spotted on the sheet to generate a concentration response curve that yielded an IC 50 value of 3.1 pmol (Fig. 4) . The IC 50 value of the staurosporine from the 96-well format was 33 nM. At a total reaction volume of 40 µL in the well, the amount of staurosporine that produced half-maximal inhibition was calculated to be 1.3 pmol. The IC 50 value for staurosporine in the µARCS was thus similar to the 96-well assay. The lowest visible inhibition spot for staurosporine corresponded to < 1 pmol, which is lower than the IC 50 value. Based on this analysis, the µARCS format was found to be sensitive enough for identifying lck inhibitors.
Thirty-seven sets containing 319,680 compounds were screened in duplicate using normal and deconvoluted sheets with the p56 lck µARCS screen. The gel images from the Viewlux were saved in a TIF format and loaded into our database for image analysis and hit picking. Images from normal and deconvoluted sheets from a representative set are depicted in Figure 5A ,B. The dark spots on the outer edges and middle of the images are the dye spots (constellation spots) that serve to orient the image in the database and act as reference points so that the locations of the compounds can be calculated. A control inhibitor was spotted outside the constellation spots at 32, 16, 8, and 4 pmol. This was required to monitor the quality and sensitivity of the assay for each run.
After correctly orienting the images by picking the constellation spots, the dark spots representing zones of inhibition were picked by clicking at the center of the spot. Initially, the most prominent spots were picked and assigned a designation of quality 1 (Q1), followed by the selection of quality 2 (Q2) and 3 (Q3) spots. The assignment of quality is based on size and intensity of the spot to provide a qualitative categorization of the potential hits, based on the screener's discretion, and hence is very subjective. Picking of hits from a sheet takes approximately 2 to 4 min. In Figure 7A , some Q1, Q2, and Q3 spots are marked. After the picks were made and saved for a pair of sheets (normal and deconvoluted), the database then analyzed the selected spots and assigned matched status to those spots that have compounds in the first 2 shells (9-compound grid) in common. Any spots with no matching compounds on the other sheet were considered unmatched spots, and the screener tested up to 25 compounds to attempt to confirm the activity on retest sheets. Some of the matched and unmatched spots are shown in Figure 5A Retest compounds were tested in duplicate in the µARCS format, whereby the density of compounds per sheet is limited to 384 to positively identify a single compound from a zone of activity by its spatial location. A total of 728 compounds reconfirmed activity in retesting, and IC 50 values for these compounds were determined in a 96-well plate format. Figure 6A ,B shows images from a representative retest sheet in duplicate. These images demonstrate the consistency and reproducibility of the assay. The retest images were loaded into the database and picked; a positive selection of a compound on any retest sheet will generate a request for IC 50 determination. The positive and negative retest results for a compound are applied back to the spot record that they originated from in the database; this allows the screener to track the status of a zone of inhibition. Positive status is for spots that have active retest compounds associated with them; negative status indicates that no active compounds were found in a 25-compound grid centered on the pick (a 5 × 5 compound array). The dose-dependent inhibition of the enzyme by these compounds was performed in a plate assay, and IC 50 curves were generated in the database after entering the data. In most cases, there is a good correlation between spot size and intensity on the primary and retest screening sheets, as well as the IC 50 values of the compounds. Three compounds with IC 50 s of 0.2, 1, and 9 µM are highlighted in Figure 7 . As shown, the compound with an IC 50 of 0.2 µM produced darker and larger spots in primary and retest sheets than the compound with an IC 50 of 9 µM. The spot size and intensity may also be influenced by the solubility and diffusion characteristics of the compounds.
The results from the entire screen are shown in Table 1 . The results are grouped according to quality and the total spots from both normal and deconvoluted sheets. The confirmation rate was better for quality 1 spots (Q1, 55%) than lower quality spots (Q2, 38%; Q3, 36%). The reconfirmation rate was lower for this assay when compared to several other µARCS screens run in our lab. We attribute this to the aggressive spot picking by the screener and a higher hit rate in the assay. The IC 50 distribution of the active compounds discovered in this screen is shown in Table 2 . There were 493 active compounds with IC 50 values of less than 100 µM; several of these compounds had IC 50 s less than 10 µM.
The cost of primary screening in µARCS is compared to the 96well plate format (10 compounds/well) in Table 3 . The advantage of cost savings in the µARCS format is clearly illustrated: the screen was 10-fold less expensive to run in the µARCS format than in our 10-compound/well mixed 96-well format 11 and 100-fold less expensive than if the screen had been run in 96-well plates with 1 compound per well in duplicate. Because the enzyme was produced internally, it is not added into the cost comparison. A sheet set containing 8640 compounds in duplicate required 40 µg of enzyme, whereas 8 µg of enzyme was needed for 9600 compounds in duplicate when screened as 10 mixtures and 80 µg if screened as singles.
CONCLUSIONS
In this study, we used the µARCS technology to identify inhibitors of the p56 lck enzyme using a homogeneous time-resolved fluorescence format. The assay, developed initially in the 96-well plates, was easily transferable to the µARCS format. The µARCS screen for lck was simple, as it only required a single gel, yet the data were robust and reproducible, and 70,000 compounds in duplicate were screened in an 8-h day. Use of paper to deliver the ATP and EDTA increased the efficiency of screening by reducing the time for the gel preparation, and by converting the assay from the plate into the µARCS format, we achieved 90% cost reduction in the primary screening. The µARCS for p56 lck enhanced the throughput of screening without requiring costly liquid-handling robotic systems and identified several potent inhibitors. 
